ACL Australian Clinical Labs Limited

Dr. Reddy's Laboratories Ltd. (500124.BY) said Wednesday it has received final approval from the U.S. Food and Drug Administration to sell a generic version of GlaxoSmithKline PLC's (GSK) Arixtra injection, which prevents blood clots after surgery.

The approval is for 2.5 milligram per 0.5-milliliter, 5.0 mg per 0.4-ml, 7.5 mg per 0.6-ml and 10 mg per 0.8-ml doses of fondaparinux sodium in pre-filled, single-dose syringes, the Indian generic drug maker said in a statement.

Dr. Reddy's will manufacture fondaparinux under license using a patented process developed by Alchemia Ltd. (ACL.AU).

-By Rumman Ahmed, Dow Jones Newswires; 91-9845104173; rumman.ahmed@dowjones.com

Australian Clinical Labs (ASX:ACL)
過去 株価チャート
から 5 2024 まで 6 2024

Australian Clinical Labs (ASX:ACL)
過去 株価チャート
から 6 2023 まで 6 2024